HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4-hydroxyperoxycyclophosphamide

the active metabolite of cyclophosphamide

Also Known As:

4-HOO-CP; 4-hydroxyperoxy-cyclophosphamide

Networked: 8 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Halogenated Hydrocarbons: 42
    - Mustard Compounds: 3
      - Nitrogen Mustard Compounds: 2
        Phosphoramide Mustards: 5
        Cyclophosphamide: 25473
        4-hydroxyperoxycyclophosphamide: 8
- Organophosphorus Compounds: 300
  - Phosphoramides: 8
    - Phosphoramide Mustards: 5
      - Cyclophosphamide: 25473
        4-hydroxyperoxycyclophosphamide: 8

Experts

1.	DeClerck, Yves A: 1 article (10/2007)
2.	Groshen, Susan G: 1 article (10/2007)
3.	Moats, Rex A: 1 article (10/2007)
4.	Nelson, Marvin D: 1 article (10/2007)
5.	Peng, Hongjun: 1 article (10/2007)
6.	Reynolds, C Patrick: 1 article (10/2007)
7.	Sohara, Yasuyoshi: 1 article (10/2007)
8.	Ye, Wei: 1 article (10/2007)
9.	Abe, Tomoyuki: 1 article (09/2003)
10.	Hayashi, Tsuyoshi: 1 article (09/2003)

Related Diseases

1.	Neoplasms (Cancer) 01/01/1996 - "Positive selection of CD34-positive hematopoietic progenitor cells as well as negative purging methods such as incubation with 4-hydroxyperoxy-cyclophosphamide (4-HC) were evaluated with respect to tumor cell depletion. " 02/01/1998 - "Sixty-two percent of sensitive FCAs were observed in tumors tested against the activated analog of cyclophosphamide, 4-hydroxyperoxycyclophosphamide (4-HC), where a sensitivity rate (# samples sensitive/total tested against agent) of 64% (95 % CI, 36.6-77.9%) was noted. " 01/01/1995 - "Although the cells from each of the three tumors show increased expression of early response genes after exposure to cisplatin (CDDP; 100 microM, 2 h) or 4-Hydroxyperoxycyclophosphamide (4-HC; 100 microM, 2 h) in culture, in mRNA extracted from tumor tissue these changes are absent or very small. "
2.	Glioma (Gliomas) 02/01/1998 - "Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC)." 02/01/2001 - "To evaluate this drug for the treatment of brain tumors, we studied the use of BSO for potentiating the antineoplastic effect of 4-hydroxyperoxycyclophosphamide (4-HC) in the rat 9L glioma model. "
3.	Cholangiocarcinoma 09/01/2003 - "Transfection of the GSTP1-1 antisense expression vector into a human cholangiocarcinoma cell line (HuCCT1) apparently decreased its intracellular GSTP1-1 concentration, and the sensitivity of transfectants to adriamycin (ADR), cisplatin, and alkylating agents such as melphalan and 4-hydroxyperoxycyclophosphamide (4-HC) was increased significantly, compared with that of mock transfectants. "
4.	Teratocarcinoma 06/01/1995 - "The teratocarcinoma cell line 833K and its relatively cisplatin-resistant subline 833K/63CP 10 were used to assess the cytotoxicity of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), cisplatin, and 4-hydroxyperoxycyclophosphamide quantitatively. "
5.	Ovarian Neoplasms (Ovarian Cancer) 06/01/1995 - "Monolayers of immortalized ovarian cancer cell lines and primary ovarian cancer cells obtained from ascites were grown in the presence of cisplatin, 4-hydroxyperoxy-cyclophosphamide (the active metabolite of cyclophosphamide) or paclitaxel. "

Related Drugs and Biologics

1.	Cisplatin (Platino)
2.	Paclitaxel (Taxol)
3.	Cyclophosphamide (Cytoxan)
4.	Messenger RNA (mRNA)
5.	Melphalan (Alkeran)
6.	Doxorubicin (Adriamycin)
7.	Antineoplastic Agents (Antineoplastics)
8.	Alkylating Agents
9.	Zoledronic Acid (Zometa)